Oct. 23 at 9:07 PM
$AGEN
Just read the Lancet paper on zanzalintinib. Response is not as good as bot/bal but its a phase 3 with hundreds of pts so cannot really compare. However, toxicity seems significant which is a game changer for 3rd line treatment
Also read the final NICHE results in Nature. Only abstract. I dont have access to full text. Results are subpar to bot/bal
Finally, read the ESMO abstract on regorafenib/bot/bal combo => Very few responses but bot dose was only 25 mg. For comparison, in our phase 2 dose was 75/150 mg. But still significant toxicity due to TKIs at that dose.
My conclusion:
1. Bot/bal is still the best IO combo - at least for colorectal.
2. Combinations with TKIs will not work well, primarily 2/2 DLTs